A significant proportion of patients with multiple sclerosis who receive interferon beta (IFNβ) therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if HLA class I and II alleles are associated with development of NAbs against IFNβ we analyzed whether NAb status and development of NAb titers high enough to be biologically relevant (>150 tenfold reduction units/ml) correlated with the HLA allele group carriage in a cohort of 903 Swedish patients with multiple sclerosis treated with either intramuscular IFNβ-1a, subcutaneous IFNβ-1a or subcutaneous IFNβ-1b. Carriage of HLA-DRB1*15 was associated with increased risk of developing NAbs and high NAb titers. After stratification based on type of IFNβ preparation, HLA-DRB1*15 carriage was observed to increase the risk of developing NAbs as well as high NAb titers against both subcutaneous and intramuscular IFNβ-1a. Furthermore, in patients receiving subcutaneous IFNβ-1a carriage of HLA-DQA1*05 decreased the risk for high NAb titers. In IFNβ-1b treated patients, HLA-DRB1*04 increased the risk of developing high NAb titers, and in a subgroup analysis of DRB1*04 alleles the risk for NAbs was increased in DRB1*04:01 carriers. In conclusion, there is a preparation-specific genetically determined risk to develop NAbs against IFNβ high enough to be clinically relevant in treatment decisions for patients with multiple sclerosis if confirmed in future studies. However, choice of IFNβ preparation still remains the single most significant determinant for the risk of developing NAbs.
References
[1]
PRISM Study Group, University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56: 1628–1636. doi: 10.1212/wnl.56.12.1628
[2]
MS Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43: 655–661. doi: 10.1212/wnl.43.4.655
[3]
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285–294. doi: 10.1002/ana.410390304
[4]
Hesse D, Sellebjerg F, Sorensen PS (2009) Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 73: 372–377. doi: 10.1212/wnl.0b013e3181b04c98
[5]
Sominanda A, Hillert J, Fogdell-Hahn A (2008) In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 79: 57–62. doi: 10.1136/jnnp.2007.122549
[6]
Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, et al. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65: 40–47. doi: 10.1212/01.wnl.0000171747.59767.5c
[7]
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184–1191. doi: 10.1016/s0140-6736(03)14541-2
[8]
Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, et al. (2013) The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 260: 1562–1568. doi: 10.1007/s00415-012-6829-3
[9]
Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P (2004) Immunogenicity of interferon beta: differences among products. J Neurol 251 Suppl 2II15–II24. doi: 10.1007/s00415-004-1204-7
[10]
Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, et al. (2011) Incorporation of an interferon-beta neutralizing antibody assay into routine clinical practice. Mult Scler 17: 1333–1340. doi: 10.1177/1352458511412654
[11]
Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP (2011) Frequency and Magnitude of Interferon beta Neutralizing Antibodies in the Evaluation of Interferon beta Immunogenicity in Patients with Multiple Sclerosis. J Interferon Cytokine Res 31: 337–344. doi: 10.1089/jir.2010.0038
[12]
Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, et al. (2012) Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 18: 610–615. doi: 10.1177/1352458511426738
[13]
Jensen PE, Sellebjerg F, Sondergaard HB, Sorensen PS (2012) Correlation between anti-interferon-beta binding and neutralizing antibodies in interferon-beta-treated multiple sclerosis patients. Eur J Neurol 19: 1311–1317. doi: 10.1111/j.1468-1331.2012.03721.x
[14]
Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, et al. (2012) Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 18: 1775–1781. doi: 10.1177/1352458512446036
[15]
Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, et al. (2007) Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13: 208–214. doi: 10.1177/1352458506070762
[16]
Barnard JG, Babcock K, Carpenter JF (2013) Characterization and quantitation of aggregates and particles in interferon-beta products: potential links between product quality attributes and immunogenicity. J Pharm Sci 102: 915–928. doi: 10.1002/jps.23415
[17]
Bozhinov A, Handzhiyski Y, Genov K, Daskalovska V, Niwa T, et al. (2012) Advanced glycation end products contribute to the immunogenicity of IFN-beta pharmaceuticals. J Allergy Clin Immunol 129: 855–858. doi: 10.1016/j.jaci.2011.10.035
[18]
Stickler M, Valdes AM, Gebel W, Razo OJ, Faravashi N, et al. (2004) The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta. Genes Immun 5: 1–7. doi: 10.1038/sj.gene.6364027
[19]
Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 118: 42–50. doi: 10.1016/j.clim.2005.08.017
[20]
Buck D, Cepok S, Hoffmann S, Grummel V, Jochim A, et al. (2011) Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 68: 480–487. doi: 10.1001/archneurol.2011.65
[21]
Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermuller J, et al. (2008) HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Human Genet 83: 219–227. doi: 10.1016/j.ajhg.2008.09.016
[22]
Weber F, Cepok S, Wolf C, Berthele A, Uhr M, et al. (2012) Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-beta therapy in multiple sclerosis patients. Pharmacogenomics J 12: 238–245. doi: 10.1038/tpj.2011.14
[23]
Olerup O, Zetterquist H (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue antigens 39: 225–235. doi: 10.1111/j.1399-0039.1992.tb01940.x
[24]
Dilthey AT, Moutsianas L, Leslie S, McVean G (2011) HLA*IMP–an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 27: 968–972. doi: 10.1093/bioinformatics/btr061
[25]
International Multiple Sclerosis Genetics Consortium (IMSGC) (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.
[26]
Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, et al. (2013) Multi-population classical HLA type imputation. PLoS Comput Biol 9: e1002877. doi: 10.1371/journal.pcbi.1002877
[27]
Cortes A, Brown MA (2011) Promise and pitfalls of the Immunochip. Arthritis Res Ther 13: 101. doi: 10.1186/ar3204
[28]
Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, et al. (2007) Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 321: 19–31. doi: 10.1016/j.jim.2006.12.012
[29]
Kawade Y (1986) Quantitation of neutralization of interferon by antibody. Methods Enzymol 119: 558–573. doi: 10.1016/0076-6879(86)19076-8
[30]
Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, et al. (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54: 38–46. doi: 10.1002/art.21575
[31]
R_Development_Core_Team (2011) R: A Language and Environment for Statistical Computing.
[32]
Schlesselman JJ, Stolley PD (1982) Case-Control Studies: Design, Conduct, Analysis. New York Oxford University Press 354 p.
[33]
Nielsen M, Lund O (2009) NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 10: 296. doi: 10.1186/1471-2105-10-296
[34]
Nielsen M, Lundegaard C, Lund O (2007) Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 8: 238. doi: 10.1186/1471-2105-8-238
[35]
Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, et al. (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48: 706–712. doi: 10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v
[36]
Ahlers JD, Belyakov IM (2010) Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines. Trends Mol Med 16: 478–491. doi: 10.1016/j.molmed.2010.07.007
[37]
Dengjel J, Rammensee HG, Stevanovic S (2005) Glycan side chains on naturally presented MHC class II ligands. J Mass Spectrom 40: 100–104. doi: 10.1002/jms.780
[38]
Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL (2006) Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 18: 92–97. doi: 10.1016/j.coi.2005.11.015
[39]
Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, et al. (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29: 497–510. doi: 10.1016/j.immuni.2008.07.013
